Abstract: PD0325901, recently approved under the generic name mirdametinib (GOMEKLI™), is an oral, highly selective, and potent non-ATP competitive inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). In February 2025, mirdametinib received its first regulatory approval from the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients (2 years of age and older) with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. This comprehensive review synthesizes the current literature on mirdametinib, detailing its pharmacological activity, molecular mechanism of action, and structure-activity relationship. Furthermore, it discusses the current clinical limitations of the drug, including its toxicity profile—such as dermatological, gastrointestinal, and ocular adverse events—and explores future perspectives, including its potential in combination therapies and expanded indications for other MAPK-driven malignancies.
1. Introduction
Neurofibromatosis type 1 (NF1) is a common autosomal-dominant hereditary tumor predisposition syndrome, affecting approximately 1 in 3000 individuals worldwide [2][3]. The disorder is caused by pathogenic variants in the NF1 tumor suppressor gene located on chromosome 17q11.2, which leads to a loss of function of the protein neurofibromin [1][2]. Neurofibromin normally acts as a negative regulator of RAS activity; its deficiency results in the constitutive activation of the RAS/RAF/MEK/ERK signaling cascade, driving uncontrolled cell proliferation and tumor growth [1][3].
Up to 50% of patients with NF1 develop plexiform neurofibromas (PN), which are histologically benign peripheral nerve sheath tumors that can cause severe and debilitating morbidities, including pain, disfigurement, motor dysfunction, and airway compression [1][3]. Furthermore, these tumors carry a lifetime risk of malignant transformation [3]. Historically, complete surgical resection was the only treatment option, but it is often unfeasible due to the tumors' extensive growth and invasion into surrounding vital structures [1][2]. The elucidation of the molecular pathogenesis of NF1 has paved the way for targeted medical therapies. Mirdametinib (PD0325901) is a novel MEK1/2 inhibitor that received its first FDA approval on February 11, 2025, for the treatment of adult and pediatric patients (≥2 years) with symptomatic, inoperable NF1-associated PN [1][4].
2. Pharmacological Activity
Mirdametinib has demonstrated significant clinical efficacy in reducing the volume of NF1-associated plexiform neurofibromas and alleviating associated symptoms. In the pivotal Phase IIb ReNeu trial (NCT03962543), mirdametinib provided durable clinical benefits. In the adult cohort, the blinded independent central review (BICR)-confirmed objective response rate (ORR) was 41%, while the pediatric cohort achieved an ORR of 52% [1]. Deep tumor volume reductions were observed, with a median best percentage change in target PN volume of −41% in adults and −42% in pediatric patients [1]. Earlier Phase II data (NF106 trial) also showed a 42% partial response rate in adolescents and adults, with a median decrease in tumor volume of 17.1% [1][2][3].
Beyond tumor shrinkage, mirdametinib treatment is associated with clinically meaningful improvements in patient-reported outcomes (PROs). Patients reported significant early and sustained reductions in worst tumor pain severity and pain interference, alongside improvements in health-related quality of life (HRQOL) [1][4].
Pharmacokinetically, mirdametinib is administered orally (as capsules or tablets for oral suspension) and reaches maximum concentration in 0.8 to 1.1 hours post-dose [1]. Steady state is achieved in approximately 6 days. The drug is highly protein-bound (>99%) and is primarily metabolized by glucuronidation and oxidation via UGT (UGT1A6, UGT2B7) and carboxyl esterase (CES) enzymes. It exhibits a mean terminal elimination half-life of 28 hours [1].
3. Molecular Mechanism of Action
Mirdametinib is a highly selective, potent, non-ATP competitive small-molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) [1][2]. The MEK1 and MEK2 enzymes are critical downstream nodes in the RAS/RAF/MEK/ERK intracellular signaling cascade [2].
In healthy cells, neurofibromin promotes the conversion of active guanosine triphosphate (GTP)-bound RAS to its inactive guanosine diphosphate (GDP)-bound conformation. In NF1 patients, the loss of functional neurofibromin leads to hyperactive RAS, which constitutively activates RAF and subsequently MEK1/2 [2]. By binding to MEK1/2, mirdametinib blocks the kinase activity of these enzymes, thereby preventing the downstream phosphorylation and activation of extracellular signal-regulated kinase (ERK) [1][4]. In vitro and in vivo preclinical models, including TAMH cell lines and NF1 mouse models, have confirmed that PD0325901 effectively reduces p-ERK levels, induces apoptosis, and significantly inhibits neurofibroma tumor volume and cellular proliferation [1][7].
4. Structure-Activity Relationship (SAR)
PD0325901 is a second-generation synthetic analog derived from the earlier MEK inhibitor CI-1040 [5]. Chemically, it is a benzamide/benzhydroxamate derivative with the IUPAC name (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino) benzamide [1].
The structural modifications introduced in PD0325901 compared to CI-1040 were designed to improve pharmaceutical potential, metabolic stability, and binding affinity. PD0325901 exhibits subnanomolar, non-competitive inhibitory activity against purified MEK1 and MEK2, with an IC50 of 0.33 nM [5]. As an allosteric inhibitor, it binds to a site distinct from the ATP-binding pocket, locking the MEK enzyme into an inactive conformation. This high specificity and affinity make PD0325901 approximately 10 times more potent than other MEK inhibitors in its class, such as AZD6244 (selumetinib) [6].
5. Current Limitations
Despite its clinical efficacy, the use of mirdametinib is constrained by several limitations, primarily related to its toxicity profile and the necessity for continuous treatment.
Adverse Events (AEs): The safety profile of mirdametinib is consistent with the class effects of MEK inhibitors. The most frequently reported treatment-related adverse events include dermatitis acneiform (rash), diarrhea, nausea, vomiting, fatigue, and paronychia [1][2][3][4]. In the ReNeu trial, dermatitis acneiform occurred in 78% of adults and 43% of pediatric patients, while paronychia was more common in children (30%) than adults (2%) [1]. These toxicities frequently necessitate dose interruptions or reductions [1][4].
Ocular and Cardiac Toxicities: Mirdametinib carries specific warnings for ocular toxicity and left ventricular dysfunction. Events such as retinal vein occlusion and blurred vision have been reported, requiring comprehensive ophthalmic assessments before and during treatment [1][5]. Additionally, asymptomatic reductions in left ventricular ejection fraction (LVEF) occur in a subset of patients (e.g., 16% of adults and 20% of pediatric patients in the ReNeu trial), mandating regular echocardiogram monitoring [1].
Treatment Duration and Resistance: Tumor shrinkage with MEK inhibitors is typically partial, and tumors may regrow if the medication is discontinued [2]. The optimal duration of therapy remains unknown, raising concerns about the long-term impact of chronic MEK inhibition on growth, development, and cognition in pediatric populations [3]. Furthermore, intrinsic or acquired resistance mechanisms exist; meta-analyses of cell lines have identified potential resistance markers to MEK inhibitors, such as the downregulation of SPRY2 and the upregulation of FZD2 and CRIM1 [6].
6. Future Perspectives
The recent FDA approval of mirdametinib marks a significant milestone, but ongoing research aims to expand its clinical utility and optimize its administration.
Expanded Indications: Mirdametinib is currently being investigated in several other MAPK-driven malignancies. Promising clinical activity has been observed in pediatric low-grade glioma (LGG) harboring MAPK pathway activations (e.g., BRAF, FGFR1, NF1 mutations) in the SJ901 trial [1]. Additional Phase II trials are recruiting patients with histiocytic disorders and vascular malformations [1].
Combination Therapies: To overcome resistance and enhance efficacy, mirdametinib is being evaluated in combination regimens. Ongoing trials are investigating its use alongside lifirafenib (a RAF dimer inhibitor) for advanced solid tumors, palbociclib for dedifferentiated liposarcoma, and chemoimmunotherapy for non-small cell lung cancer (NSCLC) [1].
Biomarker Discovery and Dosing Strategies: Future research will likely focus on identifying robust biomarkers to predict patient response and resistance, enabling more precise patient selection [2][6]. Additionally, exploring intermittent dosing schedules may help mitigate chronic toxicities while maintaining tumor suppression, which is particularly crucial for pediatric patients requiring long-term management [2].
